A new liquid enzyme product produced from its C1 technology platform called CeluStar CL will be immediately offered for sale for use in the production of wine, beer and fruit juices, said the company.
“Receiving this positive acknowledgement from the FDA regarding our GRAS notification culminates a multi-year product development process and affirms Dyadic's conclusion that its cellulase enzyme is safe for use by our customers. Dyadic intends to continue to utilize its C1 technology platform for the development of additional specialty enzyme products,” said Richard Jundzil, Dyadic's director of development & quality.
The GRAS notice is number: GRN 000292.